AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria
(Thomson Reuters ONE) -
New collaboration targeting hospital-acquired infections follows on AbCellera's
success in two previous DARPA-funded collaborations with MassBiologics.
VANCOUVER, British Columbia, July 20, 2016 (GLOBE NEWSWIRE) -- AbCellera
Biologics Inc., a biotechnology company specializing in the rapid discovery of
monoclonal antibodies from natural immune cells, today announced its third
antibody discovery collaboration with MassBiologics of the University of
Massachusetts Medical School.
This new collaboration, funded by the Defense Advanced Research Project Agency
(DARPA) under the ADEPT-PROTECT program, focuses on addressing the rapidly-
growing, unmet global health threat caused by the multidrug resistant
bacteria,Klebsiella pneumoniae. This pathogen is among the leading causes of
hospital-acquired (nosocomial) infections worldwide, and has emerged as a major
concern for patients. AbCellera will apply its single-cell antibody discovery
platform to identify panels of antibody candidates against Klebsiella
pneumoniae directly from human volunteers.
"AbCellera's technology has the throughput, speed and capacity to deeply screen
natural human antibody responses to these pathogens," said Carl Hansen, CEO and
co-founder of AbCellera. "We are pleased at the opportunity to expand our
collaboration with MassBiologics, and believe this work will further demonstrate
the strength of our approach for rapid human antibody discovery, immune
profiling, and vaccine development."
This partnership builds on the successes of two earlier DARPA-funded
collaborations between AbCellera and MassBiologics, from which novel antibodies
for potential therapeutics to enterotoxigenic E. coli and Ebola virus were
discovered.
About AbCellera Biologics Inc.
AbCellera is a privately held biotechnology company that provides enabling
technologies for the discovery and development of monoclonal antibody (mAb)
therapies directly from natural immune cells.
AbCellera's lead technology is a proprietary single cell antibody discovery
platform that provides pharma and biotech partners with the ability to rapidly
identify mAb therapeutic candidates from the natural immune repertoires of any
species, including humans. For more information, please visit www.abcellera.com
About MassBiologics
MassBiologics of the University of Massachusetts Medical School is the only
publicly owned, non-profit FDA-licensed manufacturer of vaccines and other
biologic products in the United States. The laboratory was established in 1894
by the state Board of Health to produce diphtheria antitoxin. Since that time,
the focus at MassBiologics has been to improve public health through applied
research, development and production of biologic products. In 1997, the
Commonwealth of Massachusetts transferred MassBiologics operations from the
Department of Public Health to UMass Medical School to "maintain their public
purpose, preserving their ability to compete in an increasingly competitive
marketplace and to maximize their value to the Commonwealth."
About the University of Massachusetts Medical School
The University of Massachusetts Medical School has built a reputation as a
world-class research institution, consistently producing noteworthy advances in
clinical and basic research. The Medical School attracts more than $270 million
in research funding annually, 80 percent of which comes from federal funding
sources. The mission of the Medical School is to advance the health and well-
being of the people of the commonwealth and the world through pioneering
education, research, public service and health care delivery with its clinical
partner, UMass Memorial Health Care. For more information,
visithttp://www.umassmed.edu/.
Media Contacts
Kevin Heyries
Telephone: 604-827-4151
Email: kevin.heyries(at)abcellera.com
This announcement is distributed by GlobeNewswire on behalf of
GlobeNewswire clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: AbCellera via GlobeNewswire
[HUG#2029494]
Unternehmensinformation / Kurzprofil:
Datum: 20.07.2016 - 15:00 Uhr
Sprache: Deutsch
News-ID 484370
Anzahl Zeichen: 4993
contact information:
Town:
Vancouver
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 262 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"AbCellera and MassBiologics Partner to Discover Fully Human Antibodies Against Drug-Resistant Bacteria"
steht unter der journalistisch-redaktionellen Verantwortung von
AbCellera (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
